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Background: Panax ginseng root is used in traditional oriental medicine for human health. Its main active
components such as saponins and polysaccharides have been widely evaluated for treating diseases, but
secondary active components such as oligosaccharides have been rarely studied. This study aimed to
assess the impact of water-soluble ginseng oligosaccharides (WGOS), which were isolated from the
warm-water extract of Panax ginseng root, on scopolamine-induced cognitive impairment in mice and its
antineuroinﬂammatory mechanisms.
Methods: We investigated the impact of WGOS on scopolamine-induced cognitive impairment in mice
by using Morris water maze and novel object recognition task. We also analyzed the impact of WGOS on
scopolamine-induced inﬂammatory response (e.g., the hyperexpression of proinﬂammatory cytokines IL-
1b and IL-6 and astrocyte activation) by quantitative real-time polymerase chain reaction and glial
ﬁbrillary acid protein (GFAP) immunohistochemical staining.
Results: WGOS pretreatment protected against scopolamine-induced learning and memory deﬁcits in
the Morris water maze and in the novel object recognition task. Furthermore, WGOS pretreatment
downregulated scopolamine-induced hyperexpression of proinﬂammatory cytokines interleukin (IL)-1b
and IL-6 mRNA and astrocyte activation in the hippocampus. These results indicate that WGOS can
protect against scopolamine-induced alterations in learning and memory and inﬂammatory response.
Conclusion: Our data suggest that WGOS may be beneﬁcial as a medicine or functional food supplement
to treat disorders with cognitive deﬁcits and increased inﬂammation.
Copyright  2015, The Korean Society of Ginseng, Published by Elsevier. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is characterized by the progressive loss
of memory and deterioration of cognitive function. The patholog-
ical hallmark of AD is the presence of b-amyloid (Ab) plaques. The
accumulation of Abmay trigger the degeneration of the cholinergic
system in the basal forebrain and result in dementia [1]. Acetyl-
cholinesterase inhibitors, which elevate acetylcholine levels in the
brain, are accordingly clinically utilized for treating AD [2];llege of Basic Medical Sciences, Jil
First Hospital of Jilin University, N
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d/4.0/).however, this treatment only improves symptoms of AD tempo-
rarily without preventing the progression of the disease [3].
Chronic inﬂammation is an invariant component in the patho-
genesis of most neurodegenerative diseases such as AD. After a
local injection of Ab, the inﬂammatory response occurs in the brain,
which is characterized by the upregulation of proinﬂammatory
cytokines and the activation of glial cells [4,5]. Activated glial cells,
along with the overexpression of proinﬂammatory cytokines such
as interleukin (IL)-1b) and IL-6 have been associated with thein University, Number 126 Xinmin Street, Changchun, Jilin, China.
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.
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nonsteroidal anti-inﬂammatory drugs were considered a potential
treatment to prevent or slow the onset of AD in epidemiologic and
clinical studies [9,10]; however, signiﬁcant adverse effects of the
drugs at high therapeutic doses were anticipated [11]. Thus, re-
searchers have shifted toward discovering natural compounds that
may decrease inﬂammation in AD [12,13].
Panax ginseng root has been used in traditional oriental med-
icine for human health, and its neuroprotective effect on different
neurologic diseases has been studied [14e16]. The main active
components of Panax ginseng such as saponins and poly-
saccharides have been widely evaluated, but secondary active
components such as ginseng oligosaccharides have not been
widely studied. Water-soluble ginseng oligosaccharides (WGOS),
which comprise polymers of 2e14 D-glucose molecules, were
recently puriﬁed from an aqueous extract of ginseng roots. Studies
have been demonstrated that WGOS exert an immunoregulatory
effect in vitro and in vivo [17,18] and display antitumor activity
[19]. Thus, we hypothesize WGOS may possess an antineuroin-
ﬂammatory effect, which may delay the development of neuro-
degenerative diseases such as AD. To investigate this possibility,
we assessed the potential protective effects of WGOS on learning
and memory defects and on the hyperexpression of proin-
ﬂammatory cytokines and astrocyte activation in a scopolamine-
induced dementia model.
To date, the only study examining the effect of ginseng oligo-
saccharides on cognition demonstrated that a mixture of oligosac-
charides and peptides from ginseng root can enhance memory in
scopolamine-induced dementia in rats; however, the mechanism
of this protection was not elucidated [20]. In the current study, we
assessed the protective effects of puriﬁed ginseng oligosaccharides
(i.e., WGOS) against the development of a cognition defect induced
by scopolamine. We found that WGOS signiﬁcantly attenuated
scopolamine-induced impairment in the Morris water maze and in
the novel object recognition task. In addition, WGOS pretreatment
attenuated scopolamine-induced hyperexpression of the inﬂam-
matory markers IL-1b and IL-6, and attenuated astrocyte activation
in all hippocampal subregions examined. The data from this study
shed light on a new potential prophylactic approach toward treating
disorders with cognitive deﬁcits and increased inﬂammation.2. Materials and methods
2.1. Animals
Male ICR mice (weight, 25e30 g; age, 6e7 weeks old) were
obtained from the Animal Center of the College of Basic Medical
Sciences in Jilin University (Jilin, China) with approval from the
Animal Research Ethics Committee. They were housed 3e4 miceTable 1
The experimental groups and drug treatments
Group Pretreatment
SAL Saline, IP
SCO Saline, IP
WGOS40 WGOS (40 mg/kg), IP
WGOS40þSCO WGOS (40 mg/kg), IP
WGOS80 WGOS (80 mg/kg), IP
WGOS80þSCO WGOS (80 mg/kg), IP
1) Three different pretreatments were administered once daily for 3 d. On Day 4 and all
the same drug as the pretreatment drug and the second injection, administered 15 min
injection, the behavior tests were administered to the mice.
IP, intraperitoneal, SAL, saline; SCO, scopolamine; WGOS, water-soluble ginseng oligosaper cage at room temperature (22  2C) with a 12-h alternating
light-dark cycle and free access to food and water. Drug treatment
was initiated 5 d after the animals arrived. All behavioral experi-
ments were performed between 8:00 A.M. and 11:00 A.M.
2.2. Drugs and experimental protocol
Water-soluble ginseng oligosaccharides obtained from the wa-
ter extract of Panax ginseng roots [17,18] was provided by Jilin
Ginseng Academy at the Changchun University of ChineseMedicine
(Changchun, China). Scopolamine hydrobromide was purchased
from Shanghai Hefeng Pharmaceutical Co., Ltd. (Shanghai, China).
Before the experiments, WGOSwas dissolved and scopolamine was
diluted with sterile 0.9% saline. All of drugs were administered
intraperitoneally (IP).
The mice were assigned to one of six groups, as indicated in
Table 1. Three different pretreatments were administered beginning
on Day 1 and continued throughout the course of the experiment, as
indicated in Fig.1. The threepretreatmentswere (1) saline, (2) 40mg/
kgWGOS, or (3) 80mg/kgWGOS. These dosages for theWGOSwere
chosen because they produce a robust protection in scopolamine-
treated mice, as demonstrated by their performance in the Morris
water maze task in our pilot studies. On Day 4 and on all subsequent
days, 15 min after the ﬁrst injection, the mice were administered a
second injection with either saline or 3 mg/kg scopolamine. The six
groups are the following (presented as pretreatment/treatment): (1)
saline/saline (SAL); (2) 40mg/kgWGOS/saline (WGOS40); (3) 80mg/
kgWGOS/saline (WGOS80); (4) saline/scopolamine (SCO); (5) 40mg/
kg WGOS/scopolamine (WGOS40þSCO); and (6) 80 mg/kg WGOS/
scopolamine (WGOS80þSCO). Thirty minutes after the second in-
jection, themice underwent the behavior tests. One subset ofmice in
each treatment group was tested with the Morris water maze. One
day after the conclusion of this test, these mice were administered
the samedrug treatmentsbefore theywere sacriﬁced forquantitative
polymerase chain reaction (qPCR) analysis. Another subset of each
treatment group was tested with the novel object recognition task.
One day after the conclusion of this test, these mice were sacriﬁced
for immunohistochemistry analysis. The timeline of experimental
protocols is shown in Fig. 1.
2.3. Behavioral tests
2.3.1. Morris water maze task
The Morris water maze is a circular pool that is 80 cm in
diameter and 40 cm high, and ﬁlled to a depth of 19 cmwith water
containing milk and maintained at 25  2C. The pool was
conceptually divided into four equal quadrants. An escape platform,
11 cm in diameter and 18 cm high, was located at a ﬁxed position in
the one quadrant and submerged 1 cm below the water surface.Experiment treatment1)
1st injection 2nd injection
Saline, IP Saline, IP
Saline, IP Scopolamine (3 mg/kg), IP
WGOS (40 mg/kg), IP Saline, IP
WGOS (40 mg/kg), IP Scopolamine (3 mg/kg), IP
WGOS (80 mg/kg), IP Saline, IP
WGOS (80 mg/kg), IP Scopolamine (3 mg/kg), IP
subsequent days, the mice were administered two injections. The ﬁrst injection was
after the ﬁrst injection, was saline or scopolamine. Thirty minutes after the second
ccharides.
Fig. 1. The timeline of the experimental protocols. Experiment 1 (Exp 1) is designed to investigate the protective effect of water-soluble ginseng oligosaccharides (WGOS) on
scopolamine-induced spatial memory impairment by using the Morris water maze. These animals were subsequently used to examine mRNA levels in the hippocampus using real-
time polymerase chain reaction (PCR). Experiment 2 (Exp 2) is designed to investigate the protective effect of WGOS on scopolamine-induced in recognition memory impairment by
using the novel object recognition task. These animals were subsequently sacriﬁced to examine glial ﬁbrillary acidic protein immunohistochemistry in the hippocampus. IHC,
immunohistochemistry; qPCR, quantitative polymerase chain reaction; Scop, scopolamine; WGOS, water-soluble ginseng oligosaccharide.
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On Day 4, the acquisition phase began, which consisted of ﬁve
training days (Days 4e8 of the timeline are coincident with training
Days 1e5) with three consecutive trials per day to ﬁnd the platform.
When a mouse reached the platform within 80 s, it was allowed to
stay on the platform for 20 s until the start of the next trial. If a
mouse did not reach the platform within 80 s, it was guided to the
platform by handlers. The time to reach the platform for all three
trials (i.e., the escape latency) was averaged.
On the day after ﬁnishing the acquisition trialdDay 9 on the
timelineda probe trial was performed in which the platform was
removed and replaced by a virtual platform in the exact same po-
sition. The mice were allowed to swim freely for 80 s. The time
spent in the platform quadrant and the number of times the mouse
crossed the virtual platformwere recorded. Swimming velocity was
computed using the video-tracking software, Ethovision (Nodulus,
Wageningen, The Netherlands).
2.3.2. Novel object recognition task
The novel object recognition task was performed in an open-
ﬁeld arena (50 cm  50 cm  40 cm) in a dimly lit, quiet room.
After 3 d of pretreatment with saline or WGOS (i.e., Days 1e3), the
task beganwith a habituation session on Day 4. During this session,
each mouse was exposed to the arena for 10 min to habituate them
to the apparatus. On Day 5 (i.e., the training session), themousewas
allowed 10 min to explore two identical objects placed in opposite
corners of the arena at 12 cm from the walls. On Day 6 (i.e., the
retention session), the mouse was again allowed 10 min to explore
two different objects, one familiar object and one novel object. To
prevent position preference, the locations of the familiar and novel
object were varied. After each trial, the arena and objects were
cleaned with 75% ethanol.
The mice’s behavior was recorded using the video-tracking
software, Ethovision (Nodulus). “Exploring” was deﬁned as hav-
ing the head oriented toward and within 2 cm of the objects. The
total exploring time for both objects and the time spent exploring
the novel object were quantiﬁed. The discrimination index, deﬁned
as the percent of time spent exploring the novel object was
calculated using Eq. (1):
discrimination index ¼ Time with novel object/total time  100%
[21]. (1)2.4. Quantitative real-time PCR
The mice were anesthetized with an overdose of barbiturate
(50 mg/kg, IP). The hippocampus was rapidly dissected and stored
at 80C. The samples were sonicated in Trizol reagent (Invitrogen
Co., Carlsbad, CA, USA) and the total RNA was extracted. The RNA
concentration and quality were determined using a microplate
reader (BioTek Epoch; Winooski, VT, USA). The cDNA was synthe-
sized using the GoScriptTM Reverse Transcription System (Promega
Co., Madison, WI, USA) and ampliﬁcation reactions were performed
using SYBR Premix Ex Taq TM (Takara Biological Co., Dalian, China).
The qPCR test was run by using ABI Prism 7900 HT (Applied Bio-
systems, Foster City, CA, USA). Fold changes were calculated by the
2DDCT method using glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) as the internal control. Ampliﬁcation of cDNA was per-
formed employing the following primers: GAPDH (forward): 50-TGT
GTC CGT CGT GGA TCT GA-30, GAPDH (reverse): 50-TTG CTG TTG
AAG TCG CAG GAG-30; IL-1b (forward): 50-ACG GAC CCC AAA AGA
TGA AG-30, IL-1b (reverse): 50-TTC TCC ACA GCC ACA ATG AG-30; IL-
6 (forward): 50-GAT AAG CTG GAG TCA CAG AAG G-30, IL-6
(reverse): 50-GGA ATG TCC ACA AAC TGA TAT GC-30; and GFAP
(forward): 50-GAA AAC CGC ATC ACC ATT CC-30, GFAP (reverse): 50-
CTT AAT GAC CTC ACC ATC CCG-30.
2.5. Immunohistochemistry
The mice were anesthetized with an overdose of the barbiturate
(50mg/kg, IP), and then perfusedwith 10mL normal saline through
the left ventricle, followed by 20 mL of 4% paraformaldehyde in
0.1M phosphate buffered saline (PBS). The brain was removed and
postﬁxed overnight in a perfusing ﬁxative. Relevant brain tissues
were dissected, embedded in parafﬁn wax, and cut into 1-mm thick
coronal sections with a microtome (RM 2245; Leica Microsystems,
Wetzlar, Germany).
Based on the atlas of the mouse brain [22], each 20th serial
section throughout the dorsal hippocampus were collected from
approximately 1.6 mm to 2.3 mm posterior of the bregma; the
sections were used for immunohistochemistry analysis in accor-
dance with previous protocols [23]. Rabbit anti-GFAP polyclonal
antibody (1:200, Boster, Wuhan, China), biotin-conjugated sec-
ondary antibody, and 3,30-diaminobenzidine (Zhongshan Golden
Bridge Inc., Beijing, China) were used for immunostaining. The
J Ginseng Res 2016;40:211e219214sections were counterstained with hematoxylin and coverslipped
with neutral balsam. Images were captured using a digital camera
(DP72; Olympus, Tokyo, Japan) connected to a light microscope
(Nikon Corp., Tokyo, Japan).
For quantiﬁcation of the immunostained cells, ﬁve sections from
the same plane within the dorsal hippocampus were examined
from each mouse. Cells that were stained brown were considered
GFAP-positive, and blue cells were considered not immunoreactive.
Using a light microscope, the GFAP-positive cells in ﬁve visual ﬁelds
of each hippocampal subregions [CA1, CA3, and the dentate gyrus
(DG)] were counted in each of the ﬁve sections at 200 magniﬁ-
cation. The results were averaged within each hippocampal sub-
region to provide a mean number of GFAP-positive cells for each
animal group.2.6. Statistical analysis
The data were analyzed using GraphPad Prism version 5 soft-
ware (GraphPad Software Inc., San Diego, CA, USA). All data are
presented as the mean the standard deviation (SD) and statistical
signiﬁcance was determined by using a series of analysis of vari-
ance (ANOVA), which included F-values. For theMorris watermaze,
the escape latency was analyzed using two-way repeated measures
ANOVA. The data from the probe trial were analyzed by one-way
ANOVA, followed by Bonferroni’s test. For all other experiments,
the data were analyzed using a one-way ANOVA, followed by
Bonferroni’s post hoc test for multiple comparisons. Statistical sig-
niﬁcance was p < 0.05. The number of mice in each experiment is
indicated in the ﬁgure legends.Fig. 2. Water-soluble ginseng oligosaccharides protect against scopolamine-induced spatial
latency during the training trials was analyzed by using two-way repeated measures of ANOV
platform quadrant and (C) the number of the virtual platform crossings during the probe tri
signiﬁcant difference between the groups for the number of virtual platform crossings.
mean SD. *p < 0.05 and **p < 0.01, compared to the saline-treated mice on the same day
ANOVA, analysis of variance; SAL, saline; SCO, scopolamine; WGOS40/WGOS80, 40 mg/kg3. Results
3.1. Water-soluble ginseng oligosaccharides protect against
scopolamine-induced spatial learning and memory impairment
Spatial learning and memory, as measured by escape latency
during the training sessions of the Morris water maze, were
signiﬁcantly different between the treatment groups [F (5,
415) ¼ 29.4, p < 0.0001]. The escape latency decreased progres-
sively over the course of the training sessions [F (4, 415) ¼ 67.47,
p < 0.0001]. However, scopolamine administration induced a more
prolonged escape latency, compared to the saline treatment for
training Days 2e5 (p < 0.01, respectively). The mice with WGOS
(40 mg/kg or 80 mg/kg) pretreatment before scopolamine had a
signiﬁcantly shorter escape latency in comparison to mice treated
with scopolamine on training Day 4 (p < 0.05 for both doses) and
Day 5 (p< 0.01 for both doses), but not on the other days (p> 0.05).
The results are presented in Fig. 2A. This ﬁnding suggests that
WGOS can not immediately attenuate the effect of scopolamine on
memory. Pretreatment/treatment with WGOS alone did not affect
the escape latency, compared to the escape latency of the saline-
treated group (p > 0.05).
The time spent in the target quadrant during the probe trial
session of the Morris water maze was not statistically different
among all groups [F (5, 83) ¼ 2.29, p ¼ 0.05, Fig. 2B]. However,
WGOS treatment at either dosage (i.e., WGOS40 þ SCO or
WGOS80 þ SCO) attenuated the slight decrease caused by scopol-
amine, but did not achieve signiﬁcance. However, a signiﬁcant
differencewas detected among the groups for the number of virtual
platform crossings [F (5, 83)¼ 13.05, p< 0.0001, Fig. 2C]. Therefore,learning and memory impairment in the Morris water maze task. (A) The mean escape
A. It signiﬁcantly differs between treatment groups and days. (B) The time spent in the
als were analyzed by one-way ANOVA, followed by Bonferroni’s post hoc test. There is a
Eighty-nine mice were tested with 14e15 animals per group. Data are presented as
. #p < 0.05 and ##p < 0.01, compared with scopolamine-treated mice on the same day.
dose/80 mg/kg dose of water-soluble ginseng oligosaccharides.
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learning and memory deﬁcits caused by scopolamine. Compared to
the saline-treated mice, the mice treated with scopolamine had a
fewer number of crossings (p < 0.01), which indicated that
scopolamine could induce spatial learning and memory impair-
ment. Pretreatment by WGOS (40 mg/kg or 80 mg/kg) attenuated
the decreased number of crossings in mice treated with scopol-
amine alone (p < 0.01, respectively), which indicated that WGOS
pretreatment markedly ameliorated scopolamine-induced spatial
learning and memory impairment. However, WGOS alone at either
dose did not positively or negatively affect memory because there
was no signiﬁcant difference between these animals and those
treated with saline alone (p > 0.05).3.2. Water-soluble ginseng oligosaccharides protect against
scopolamine-induced recognition memory impairment
To further conﬁrm the protective effect of WGOS on learning
and memory impairment, we used the novel object recognition
task. During the retention session of the novel object recognition
task, all groups exhibited similar behavior because the total time
spent exploring both objects did not differ among the groups [F (5,
80) ¼ 0.99, p ¼ 0.43, Fig. 3A]. However, the time spent exploring
the novel object, expressed as the discrimination index, was
signiﬁcantly different between the groups [F (5, 80) ¼ 5.87,
p < 0.0001, Fig. 3B]. The discrimination index in animals treated
with scopolamine alonewas approximately 50%, which represents
a chance level [21]; this level was markedly decreased in com-
parison to that of the saline-treated group (p < 0.05, Fig. 3B),
which indicated that scopolamine can induce recognition mem-
ory impairment. Pretreatment with 40 mg/kg or 80 mg/kg WGOS
before administering scopolamine increased the time spent
exploring the novel object and revealed a signiﬁcantly higher
discrimination index than scopolamine alone (p < 0.05, respec-
tively, Fig. 3B). These results indicate that WGOS pretreatment
(40 mg/kg or 80 mg/kg) markedly ameliorated scopolamine-
induced recognition memory impairment. However, WGOS
alone at either dose did not positively or negatively affect recog-
nition memory because these animals explored the novel object
for similar amounts of time, compared to the saline-treated group
(p > 0.05, respectively, Fig. 3B).Fig. 3. Water-soluble ginseng oligosaccharides (WGOS) protect against scopolamine-induce
analysis of variance shows that the total time of exploring both objects was not different. (
The Bonferroni’s post hoc test reveals that the discrimination index is lower in scopolami
retention session. Eighty-six mice were tested with 13e15 animals per group. Data are presen
to the scopolamine group. SAL, saline; SCO, scopolamine; WGOS40/WGOS80, 40 mg/kg dos3.3. Water-soluble ginseng oligosaccharides protect against
scopolamine-induced hyperexpression of proinﬂammatory
cytokines mRNA in the hippocampus
To determine whether the attenuation of scopolamine-induced
behavior by WGOS was associated with antineuroinﬂammatory
effects, we examined the mRNA expression levels of proin-
ﬂammatory cytokines IL-1b and IL-6 in the hippocampus by using
qPCR. The results are quantitated in Figs. 4A, 4B. The treatment
signiﬁcantly affected the expression of IL-1b mRNA [F (3,
14) ¼ 11.10, p ¼ 0.0005, Fig. 4A] and IL-6 mRNA [F (3, 14) ¼ 14.56,
p ¼ 0.0001, Fig. 4B] with scopolamine markedly increasing the
expression of IL-1b mRNA and IL-6 mRNA in the hippocampus,
compared to the saline-treated mice (p < 0.01 for both factors).
Pretreatment with WGOS (40 mg/kg or 80 mg/kg) prevented the
scopolamine-induced hyperexpression of IL-1bmRNA (p < 0.01 for
both doses) and IL-6 mRNA (p < 0.01 for both doses), and were
similar to the levels in the saline-treated group (p > 0.05). These
data indicate that WGOS pretreatment at either dose could atten-
uate the scopolamine-induced hyperexpression of proin-
ﬂammatory cytokines IL-1b and IL-6 mRNA in the hippocampus.3.4. Water-soluble ginseng oligosaccharides suppress scopolamine-
induced astrocyte activation in the hippocampus
Basedonearlier results,we concluded thatWGOSpretreatment at
either dose (40 mg/kg or 80 mg/kg) had similar effects on behavior
and proinﬂammatory cytokines levels. Therefore, rather than exam-
ining both doses, we only examined the effect of 40 mg/kg WGOS
pretreatment on the expressions of GFAP, a marker for astrocyte
activation. We examined the mRNA levels of GFAP using qPCR, the
morphology, and number of GFAP-positive cells by immunohisto-
chemistry in the hippocampus for three treatment groups: (1) the
saline-treated controls, (2) the scopolamine-treatedmice, and (3) the
mice pretreated with 40 mg/kg of WGOS before scopolamine
treatment.
ThemRNA levels of GFAP are quantitated in Fig. 5. The treatment
signiﬁcantly affected the expression of GFAP mRNA [F (2,
12) ¼ 37.32, p< 0.0001] with scopolamine markedly increasing the
expression of GFAP mRNA in the hippocampus, compared to the
expression in the saline-treated mice (p < 0.01). Pretreatment withd recognition memory impairment in the novel object recognition task. (A) One-way
B) By contrast, the discrimination index is signiﬁcantly different between the groups.
ne-treated mice and that this effect is attenuated by WGOS pretreatment during the
ted as mean SD. *p < 0.05, compared to the saline-treated mice. #p < 0.05, compared
e/80 mg/kg dose of water-soluble ginseng oligosaccharides.
Fig. 4. Water-soluble ginseng oligosaccharides (WGOS) protect against scopolamine-induced hyperexpression of proinﬂammatory cytokines in the hippocampus. The levels of (A)
IL-1b mRNA and (B) IL-6 mRNA in the hippocampus of each treatment group are quantitated and presented as the fold change. One-way analysis of variance shows that the
treatment signiﬁcantly affects mRNA expression of proinﬂammatory cytokines. Bonferroni’s post hoc test reveals that WGOS pretreatment prevents the scopolamine-induced
hyperexpression of IL-1b and IL-6 mRNA. Eighteen mice were used for mRNA analysis with 4e5 animals per group. Data are presented as mean SD. **p < 0.01, compared to
the saline group. ##p < 0.01, compared to the scopolamine group. SAL, saline; SCO, scopolamine; WGOS40/WGOS80, 40 mg/kg dose/80 mg/kg dose of water-soluble ginseng
oligosaccharides.
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induced by scopolamine (p < 0.01).
Fig. 6 shows representative images of GFAP-immunostained
cells. In the saline-treated mice, GFAP-positive cells were rarely
observed in any hippocampal subregion; however, when GFAP-
positive cells were present, they were small and dispersed
(Fig. 6D, 6G, 6J). For the scopolamine-treated mice, a large number
of GFAP-positive cells were evident in all hippocampal subregions,
and the cells were hypertrophied and condensed (Fig. 6E, 6H, 6K),
which is indicative of astrocyte activation. Pretreatment with
40 mg/kg WGOS attenuated scopolamine-induced astrocyte acti-
vation in all hippocampal subregions (Fig. 6F, 6I, 6L). The number of
activated astrocytes was signiﬁcantly different in all three sub-
regions: DG [F (2, 9) ¼ 29.8, p ¼ 0.0001], CA1 [F (2, 9) ¼ 25.76,
p ¼ 0.0002], and CA3 [F (2, 9) ¼ 92.01, p < 0.0001] (Fig. 7). In
particular, the number of GFAP-positive cells in all three regionsFig. 5. Water-soluble ginseng oligosaccharides (WGOS) prevent scopolamine-induced
hyperexpression of glial ﬁbrillary acid protein (GFAP) mRNA in the hippocampus. The
levels of GFAP mRNA in the hippocampus of each treatment group were quantitated
and are presented as the fold change. One-way analysis of variance shows that
treatment signiﬁcantly affected the expression of GFAP mRNA. The Bonferroni’s post
hoc test reveal that WGOS pretreatment prevents the hyperexpression of GFAP mRNA
by scopolamine. The data are presented as mean SD. Fifteen mice were used for
mRNA analysis with ﬁve animals per group. **p < 0.01, compared to the saline group.
##p < 0.01, compared to the scopolamine group. SAL, saline; SCO, scopolamine;
WGOS40, 40 mg/kg dose of water-soluble ginseng oligosaccharides.(i.e., DG, CA1, CA3) were signiﬁcantly increased in the scopolamine-
treated mice, compared to the saline-treated controls (p < 0.01,
Fig.7). When themicewere pretreatedwith 40mg/kgWGOS before
scopolamine, the increase in the number of GFAP-positive cells
triggered by scopolamine was signiﬁcantly attenuated in all hip-
pocampal subregions (p < 0.01 for all three subregions; Fig. 7),
compared to scopolamine. In the DG and CA1, the levels were
similar to those in the saline-treated group (p > 0.05 for both;
Fig. 7A, 7B), but slightly elevated in the CA3 subregion (p < 0.05;
Fig. 7C).4. Discussion
In the present study, we demonstrated for the ﬁrst time the
ability of WGOS (i.e., puriﬁed oligosaccharides from aqueous
extract of the ginseng root) to protect against scopolamine-induced
learning and memory deﬁcits in the Morris water maze and novel
object recognition task in mice.
The escape latency, the time spent in the platform quadrant, and
the number of virtual platform crossings in the Morris water maze
have been frequently used to evaluate the ability of spatial learning
and memory. In our experiments, WGOS pretreatment attenuated
the effects of scopolamine on spatial learning and memory, pre-
vented the time delay in escape latency, and decreased the number
of virtual platform crossings in the probe trial in scopolamine-
treated mice. The time spent in the platform quadrant was not
statistically different among the groups; however, this time was
slightly increased in the WGOS þSCO group, compared to the
scopolamine group. Because the number of virtual platform
crossings can most precisely reﬂect the platform’s location, we
believe thatWGOS can ameliorate the spatial learning andmemory
defect induced by scopolamine in mice.
To further conﬁrm the effects of WGOS, we also examined the
ability of WGOS to protect against scopolamine-induced recogni-
tionmemory deﬁcits by using the novel object recognition task. The
results indicated that WGOS pretreatment also protected against
recognition memory impairment caused by scopolamine, as indi-
cated by a signiﬁcantly higher discrimination index, which reﬂects
good recognition memory.
Several studies have shown that oligosaccharides from various
sources can attenuate learning and memory deﬁcits in various
animal models of AD by different mechanisms: (1) an acidic
Fig. 6. Water-soluble ginseng oligosaccharides (WGOS) prevent the scopolamine-induced activation of astrocytes in each hippocampal subregion. Representative images of glial
ﬁbrillary acid protein (GFAP)-immunopositive cells show the dorsal hippocampus in mice that received treatment with (A) saline, (B) scopolamine (3 mg/kg), or (C) WGOS (40 mg/
kg) before scopolamine (3 mg/kg). The images are at 100magniﬁcation. Higher resolution images of the morphology of astrocytes in the three hippocampal subregions (DG, CA1,
and CA3) are below the original image. Scale bar is 200 mm in AeC and 50 mm in DeL. DG, dentate gyrus; SAL, saline; SCO, scopolamine; WGOS40, 40 mg/kg dose of water-soluble
ginseng oligosaccharides.
T. Xu et al / WGOS protect cognitive deﬁcit 217oligosaccharide from brown algae attenuated scopolamine-
induced memory impairment in rats by exerting antioxidant ac-
tivity [24]; (2) a heparin-derived oligosaccharide, C3, exerts a
neuroprotective effect in cholinergic lesioned rats through
reducing cholinergic damage [25]; and (3) cyclodextrins, which are
cyclic oligosaccharides, improved spatial learning and memory
deﬁcits in Tg19959 mice and upregulated the expression of genes
involved in cholesterol transport and Ab clearance in cell and
mouse models of AD [26]. To date, the only study using ginseng
oligosaccharides is by Wang et al [20], who found that a mixture ofFig. 7. Statistical analysis of glial ﬁbrillary acid protein (GFAP)-positive cells in each hippoca
dentate gyrus (DG), (B) CA1, and (C) CA3 in mice that received treatment with saline, scopola
way analysis of variance shows that treatment signiﬁcantly affects the number of GFAP-p
attenuates the scopolamine-induced increase in the number of GFAP-positive cells. Twelve m
**p < 0.01, compared to the saline-treated mice. #p < 0.05, ##p < 0.01, compared to the scopo
soluble ginseng oligosaccharides.oligosaccharides and peptides from Panax ginseng root adminis-
tered to rats intraperitoneally could enhance memory activity in
scopolamine-induced memory deﬁcit, and enhance memory better
than piracetam; however, they did not lucubrate the mechanisms.
In the current study, we used pure ginseng oligosaccharides (i.e.,
WGOS) and examined the mechanism that protects against
scopolamine-induced memory deﬁcit in mice.
Neuroinﬂammation is an important mechanism that leads to
neurodegenerative changes in the AD brain and activated glial cells
(e.g., astrocytes and microglia). Proinﬂammatory cytokines arempal region. The mean number of GFAP-positive cells per section is counted in (A) the
mine (3 mg/kg), or WGOS (40 mg/kg) before scopolamine (3 mg/kg), respectively. One-
ositive cells. Bonferroni’s post hoc test reveals that WGOS pretreatment signiﬁcantly
ice were used with four animals per group. Data are presented as mean SD. *p < 0.05,
lamine-treated mice. SAL, saline; SCO, scopolamine; WGOS40, 40 mg/kg dose of water-
J Ginseng Res 2016;40:211e219218indicators of an inﬂammatory event in the brain. In the brains of AD
patients and animal models, the Ab-elicited expression of inﬂam-
matory genes such as IL-1b and IL-6 and inﬂammatory stimuli
induced the signaling pathway of oxidative stress and cell death
[27]. Chronic inﬂammation resulting from the recruitment of acti-
vated glial cells to Ab plaques are an invariant component
responsible for the induction of hippocampal neuronal damage
[5,28]. Therefore, controlling Ab-stimulated neuroinﬂammation
may be an important target for AD drugs, and active components
from a variety of plants have been discussed as possible anti-
inﬂammatory drug candidates for the treatment of AD [29].
Previous studies demonstrated that WGOS could exert anti-
tumor activity via its immunomodulatory effects [19], which sug-
gests thatWGOS could function as an antineuroinﬂammatory agent
and may be a potential treatment for AD. In this study, we used
scopolamine to induce learning and memory deﬁcits. The drug also
induced a strong inﬂammatory response such as the hyper-
expression of the proinﬂammatory cytokines IL-1b and IL-6 and
astrocyte activation in the hippocampus. These results were
consistent with previous reports in which scopolamine-induced
dementia via damage to the cholinergic system was complicated
by inﬂammation in the brain [13,30]. The increased expression of
IL-1b and IL-6 and astrocyte activation in the hippocampus that was
evident in mice treated with scopolamine only was attenuated by
pretreatment with WGOS. These results indicated that WGOS may
protect against scopolamine-induced learning and memory deﬁcits
by regulating the inﬂammatory response in the brain, and suggests
that this drug could have therapeutic value in the treatment of
learning and memory deﬁcits and various brain disease associated
with neuroinﬂammation.
Studies have shown that some oligosaccharides that have a low
molecular weight (MW) of 1,300e2,200 Da can enter the central
nervous system [31,32], although oligosaccharides were tradition-
ally viewed as being difﬁcult to pass through the bloodebrain
barrier (BBB). One study indicated that oligosaccharides cross the
BBB, depending on their MW, and the process of transport is
associated with glucose transporter 1 [33]. WGOS are composed of
polymers of 2e14 glucose molecules with a lower MW ranging
from 365 Da to 2,310 Da [17e19], which suggests that WGOS has
the ability to cross the BBB and mediate their effects. By contrast,
WGOS exerts an immunoregulatory effect in vivo [19]. Therefore,
WGOS possibly prevent neuroinﬂammation through the immune
system. Further studies are necessary to identify the mechanism by
which WGOS exert their effects.
In summary, our experimental results demonstrated that WGOS
pretreatment signiﬁcantly protects against scopolamine-induced
learning and memory deﬁcits in the Morris water maze and in
the novel object recognition task. Furthermore, these results indi-
cate that WGOS may protect against learning and memory deﬁcits
by regulating the inﬂammatory response in the brain. This drug
could also have a therapeutic value in the treatment of learning and
memory deﬁcits and various brain diseases associated with
neuroinﬂammation.Conﬂicts of interest
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